Abstract
The mammalian target of rapamycin complex 1 syndrome (Tors), paradigm implies an exhaustive cohesive disease entity driven by a hyperactive mTORC1, and which includes obesity, type 2 diabetic hyperglycemia, diabetic dyslipidemia, diabetic cardiomyopathy, diabetic nephropathy, diabetic peripheral neuropathy, hypertension, atherosclerotic cardiovascular disease, non-alcoholic fatty liver disease, some cancers, neurodegeneration, polycystic ovary syndrome, psoriasis and other. The TorS paradigm may account for the efficacy of standard-of-care treatments of type 2 diabetes (T2D) in alleviating the glycaemic and non-glycaemic diseases of TorS in T2D and non-T2D patients. The TorS paradigm may generate novel treatments for TorS diseases.
Original language | English |
---|---|
Article number | e3712 |
Journal | Diabetes/Metabolism Research and Reviews |
Volume | 40 |
Issue number | 1 |
DOIs | |
State | Published - Jan 2024 |
Bibliographical note
Publisher Copyright:© 2023 The Authors. Diabetes/Metabolism Research and Reviews published by John Wiley & Sons Ltd.
Keywords
- insulin
- metabolic stress
- metabolic syndrome (MetS)
- mTORC1syndrome (TorS)
- type 2 diabetes (T2D)